Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1879 1
1881 2
1882 1
1931 1
1938 1
1946 1
1947 4
1948 9
1949 2
1950 1
1951 2
1952 2
1954 3
1955 1
1956 2
1957 2
1958 1
1959 4
1962 1
1963 2
1966 2
1967 1
1968 1
1969 4
1970 2
1971 2
1972 5
1973 6
1974 5
1975 2
1976 1
1977 4
1978 1
1979 5
1980 4
1981 4
1982 2
1983 5
1984 1
1985 5
1986 4
1987 2
1988 12
1989 4
1990 9
1991 5
1992 9
1993 13
1994 11
1995 6
1996 11
1997 8
1998 10
1999 13
2000 21
2001 19
2002 28
2003 18
2004 15
2005 15
2006 9
2007 16
2008 22
2009 22
2010 19
2011 21
2012 41
2013 35
2014 34
2015 32
2016 42
2017 39
2018 47
2019 53
2020 68
2021 73
2022 65
2023 59
2024 47
2025 40

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,012 results

Results by year

Filters applied: . Clear all
Page 1
Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis.
Bieber T, Simpson EL, Silverberg JI, Thaçi D, Paul C, Pink AE, Kataoka Y, Chu CY, DiBonaventura M, Rojo R, Antinew J, Ionita I, Sinclair R, Forman S, Zdybski J, Biswas P, Malhotra B, Zhang F, Valdez H; JADE COMPARE Investigators. Bieber T, et al. Among authors: sinclair r. N Engl J Med. 2021 Mar 25;384(12):1101-1112. doi: 10.1056/NEJMoa2019380. N Engl J Med. 2021. PMID: 33761207 Clinical Trial.
Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials.
Kimball AB, Jemec GBE, Alavi A, Reguiai Z, Gottlieb AB, Bechara FG, Paul C, Giamarellos Bourboulis EJ, Villani AP, Schwinn A, Ruëff F, Pillay Ramaya L, Reich A, Lobo I, Sinclair R, Passeron T, Martorell A, Mendes-Bastos P, Kokolakis G, Becherel PA, Wozniak MB, Martinez AL, Wei X, Uhlmann L, Passera A, Keefe D, Martin R, Field C, Chen L, Vandemeulebroecke M, Ravichandran S, Muscianisi E. Kimball AB, et al. Among authors: sinclair r. Lancet. 2023 Mar 4;401(10378):747-761. doi: 10.1016/S0140-6736(23)00022-3. Epub 2023 Feb 3. Lancet. 2023. PMID: 36746171 Clinical Trial.
A review of the treatment of male pattern hair loss.
York K, Meah N, Bhoyrul B, Sinclair R. York K, et al. Among authors: sinclair r. Expert Opin Pharmacother. 2020 Apr;21(5):603-612. doi: 10.1080/14656566.2020.1721463. Epub 2020 Feb 17. Expert Opin Pharmacother. 2020. PMID: 32066284 Review.
Two Phase 3 Trials of Baricitinib for Alopecia Areata.
King B, Ohyama M, Kwon O, Zlotogorski A, Ko J, Mesinkovska NA, Hordinsky M, Dutronc Y, Wu WS, McCollam J, Chiasserini C, Yu G, Stanley S, Holzwarth K, DeLozier AM, Sinclair R; BRAVE-AA Investigators. King B, et al. Among authors: sinclair r. N Engl J Med. 2022 May 5;386(18):1687-1699. doi: 10.1056/NEJMoa2110343. Epub 2022 Mar 26. N Engl J Med. 2022. PMID: 35334197 Clinical Trial.
Skin-to-skin contact after birth: Developing a research and practice guideline.
Brimdyr K, Stevens J, Svensson K, Blair A, Turner-Maffei C, Grady J, Bastarache L, Al Alfy A, Crenshaw JT, Giugliani ERJ, Ewald U, Haider R, Jonas W, Kagawa M, Lilliesköld S, Maastrup R, Sinclair R, Swift E, Takahashi Y, Cadwell K. Brimdyr K, et al. Among authors: sinclair r. Acta Paediatr. 2023 Aug;112(8):1633-1643. doi: 10.1111/apa.16842. Epub 2023 May 24. Acta Paediatr. 2023. PMID: 37166443
Healthy hair: what is it?
Sinclair RD. Sinclair RD. J Investig Dermatol Symp Proc. 2007 Dec;12(2):2-5. doi: 10.1038/sj.jidsymp.5650046. J Investig Dermatol Symp Proc. 2007. PMID: 18004288 Free article. Review.
Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: A randomized phase 2b clinical trial.
Ezzedine K, Peeva E, Yamaguchi Y, Cox LA, Banerjee A, Han G, Hamzavi I, Ganesan AK, Picardo M, Thaçi D, Harris JE, Bae JM, Tsukamoto K, Sinclair R, Pandya AG, Sloan A, Yu D, Gandhi K, Vincent MS, King B. Ezzedine K, et al. Among authors: sinclair r. J Am Acad Dermatol. 2023 Feb;88(2):395-403. doi: 10.1016/j.jaad.2022.11.005. Epub 2022 Nov 9. J Am Acad Dermatol. 2023. PMID: 36370907 Free article. Clinical Trial.
Porokeratosis.
Awad A, Nirenberg A, Colla TG, Sinclair R. Awad A, et al. Among authors: sinclair r. Clin Exp Dermatol. 2024 Nov 22;49(12):1733-1734. doi: 10.1093/ced/llae192. Clin Exp Dermatol. 2024. PMID: 38747355 No abstract available.
Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2).
Kwon O, Senna MM, Sinclair R, Ito T, Dutronc Y, Lin CY, Yu G, Chiasserini C, McCollam J, Wu WS, King B. Kwon O, et al. Among authors: sinclair r. Am J Clin Dermatol. 2023 May;24(3):443-451. doi: 10.1007/s40257-023-00764-w. Epub 2023 Mar 1. Am J Clin Dermatol. 2023. PMID: 36855020 Free PMC article. Clinical Trial.
1,012 results